PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Recovery”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 163 records · Page 9Linked to original sources
PubMed2006

Renal perfusion: comparison of saturation-recovery TurboFLASH measurements at 1.5T with saturation-recovery TurboFLASH and time-resolved echo-shared angiographic technique (TREAT) at 3.0T.

PURPOSE: To investigate the dependence of semiquantitative renal perfusion parameters on the acquisition technique and field strength used. MATERIALS AND METHODS: After intravenous injection of 7-mL Gd-chelates, high-temporal-resolution turbo fast low-angle shot (TurboFLASH) renal perfusion measurements were performed on eight healthy volunteers at 1.5T and another eight healthy volunteers at 3.0T. Another eight healthy volunteers were examined at 3.0T using time-resolved echo-shared angiographic technique (TREAT) after bolus administration of 7-mL Gd-chelates with a temporal resolution of 1.4 seconds. Analysis of the first-pass perfusion data yielded the following semiquantitative renal perfusion indices: mean transit time (MTT), time to peak (TTP), maximal upslope (MUS), and maximal signal intensity (MSI). RESULTS: MTT and TTP did not show significant differences between the different techniques. MSI and MUS were significantly (P < or = 0.002) higher with TREAT (591.1 a.u./second and 103.5 a.u./second) than with TurboFLASH at both field strengths (1.5T: 400.5 a.u./second and 65.4 a.u./second; 3.0T: 362.2 a.u./second and 68.7 a.u./second). CONCLUSION: Semiquantitative renal perfusion measurements are feasible with time-resolved echo-shared sequences and TurboFLASH techniques. While MTT and TTP appear to be independent of the technique and field strength applied, MUS and MSI are higher with TREAT.

Adult↗
PubMed2000

Immunosuppression and recovery of drug-impaired host resistance against Candida albicans infection by oxoglaucine.

The immunosuppressive action of aporphinoid alkaloid oxoglaucine was studied in experimental Candida albicans (C. albicans) infection in mice. The alkaloid augmented host resistance to pathogen applied to mice (6-8 weeks of age) at a low dose of 2 mg kg(-1) in 3 days and impaired it at a high dose of 10 mg kg(-1). The suppressive activity observed under the latter schedule correlated with the inhibited proliferative response of splenic cells to mitogens and with decreased popliteal lymph node (PLN) reaction to C. albicans. Treatment of mice with oxoglaucine (at the age of 5 days) at a dose of 5 mg kg(-1) in 3 consecutive days increased the susceptibility to Candida inoculation at the age of 6 weeks. Delayed type hypersensitivity (DTH) response to C. albicans was enhanced after pretreatment of adult mice and was suppressed after administration to newborn mice. Long-time treatment (10 days) with oxoglaucine, cyclophoshamide or prednisolone at a dose of 10 mg kg(-1) increased the rate of mortality of Candida-infected mice. Combined pretreatment of mice with cyclophosphamide or prednisolone (5 days at a dose of 5 mg kg(-1)) followed by oxoglaucine (5 days at a dose of 5 mg kg(-1)), prolonged the survival of infected mice.

Animals↗